10.15.09
Azopharma Product Development Group and PharmaNet Development Group have formed a business development and co-promotion alliance to leverage complementary services, develop business opportunities, and jointly manage projects for certain services provided by the two companies.
Phil Meeks, Azopharma's chief executive officer, commented, "This agreement is an exciting opportunity for both of our organizations. Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development."
Jeffrey P. McMullen, PharmaNet's president and chief executive officer, added, "PharmaNet's and Azopharma's services complement each other. Azopharma is an established provider of in vivo services with preclinical and toxicology capabilities and our bioanalytical capabilities are ideally positioned to support these studies."
Phil Meeks, Azopharma's chief executive officer, commented, "This agreement is an exciting opportunity for both of our organizations. Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development."
Jeffrey P. McMullen, PharmaNet's president and chief executive officer, added, "PharmaNet's and Azopharma's services complement each other. Azopharma is an established provider of in vivo services with preclinical and toxicology capabilities and our bioanalytical capabilities are ideally positioned to support these studies."